CN110312721A - 墨蝶呤的多晶型物 - Google Patents

墨蝶呤的多晶型物 Download PDF

Info

Publication number
CN110312721A
CN110312721A CN201780084819.2A CN201780084819A CN110312721A CN 110312721 A CN110312721 A CN 110312721A CN 201780084819 A CN201780084819 A CN 201780084819A CN 110312721 A CN110312721 A CN 110312721A
Authority
CN
China
Prior art keywords
crystalline form
mopterin
mupterin
crystalline
free base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780084819.2A
Other languages
English (en)
Chinese (zh)
Inventor
H.尤施诺
T.科莫达
T.马楚莫托
K.基施莫托
S.穆拉塔
Y.施罗
D.E.莱维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xiansha Pharmaceutical Co
Original Assignee
Xiansha Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiansha Pharmaceutical Co filed Critical Xiansha Pharmaceutical Co
Publication of CN110312721A publication Critical patent/CN110312721A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201780084819.2A 2016-11-29 2017-11-28 墨蝶呤的多晶型物 Pending CN110312721A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662427686P 2016-11-29 2016-11-29
US62/427686 2016-11-29
PCT/US2017/063515 WO2018102314A1 (en) 2016-11-29 2017-11-28 Polymorphic form of sepiapterin

Publications (1)

Publication Number Publication Date
CN110312721A true CN110312721A (zh) 2019-10-08

Family

ID=62241955

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780084819.2A Pending CN110312721A (zh) 2016-11-29 2017-11-28 墨蝶呤的多晶型物

Country Status (8)

Country Link
US (2) US11130760B2 (https=)
EP (1) EP3548487A4 (https=)
JP (1) JP7148532B2 (https=)
CN (1) CN110312721A (https=)
CA (1) CA3043499A1 (https=)
MA (1) MA46972A (https=)
MX (1) MX391156B (https=)
WO (1) WO2018102314A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117117299A (zh) * 2023-08-14 2023-11-24 国联汽车动力电池研究院有限责任公司 一种无机硫化物固体电解质及其制备方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2562176B1 (en) 2010-04-22 2018-08-15 Nihon University Medicinal agent and beverage/food for preventing cerebral dysfunction and improving same
MA46973A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Polymorphes de sépiaptérine et leurs sels
MA46972A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Forme polymorphe de sépiaptérine
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
FI3801536T3 (fi) 2018-05-30 2024-08-29 Ptc Therapeutics Mp Inc Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi
EP3801534B1 (en) 2018-05-30 2026-02-18 PTC Therapeutics MP, Inc. Treatment of phenylketonuria with sepiapterin
AU2019277372B2 (en) 2018-05-30 2024-12-19 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin
IL290321B1 (en) 2019-08-05 2026-04-01 Ptc Therapeutics Inc Use of spiapterin and its metabolites for radiation exposure treatment
IL291565B1 (en) 2019-09-25 2026-04-01 Ptc Therapeutics Inc Method for treating phenylalanine irregularity
EP4093405A1 (en) 2020-01-24 2022-11-30 PTC Therapeutics MP, Inc. Methods for treating parkinson's disease with sepiapterin
WO2022173823A1 (en) 2021-02-09 2022-08-18 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin
IL305037A (en) 2021-02-09 2023-10-01 Ptc Therapeutics Mp Inc Methods of treating glioblastomas with spiafatrin
PE20241579A1 (es) 2021-09-29 2024-08-01 Ptc Therapeutics Inc Composicion farmaceutica de sepiapterina

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4758571A (en) * 1982-03-03 1988-07-19 Kanegafuchi Chemical Industry Company, Limited Pterin derivatives to treat Parkinson's disease
CN1905863A (zh) * 2003-11-17 2007-01-31 生物马林药物股份有限公司 用于治疗代谢紊乱的方法和组合物
CN101678025A (zh) * 2007-04-11 2010-03-24 生物马林药物股份有限公司 四氢生物蝶呤组合物及其测量方法
CN104736539A (zh) * 2012-05-07 2015-06-24 白鸟制药株式会社 墨蝶呤和四氢乳酰蝶呤的制造法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0722731B1 (en) 1994-08-05 2002-06-05 Suntory Limited Remedy for spinocerebellar degeneration
JP2002515965A (ja) 1995-08-18 2002-05-28 ダブリュー． ランドリ，ドナルド 抗体触媒反応の調節による有機化合物の検出
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
JP2007509909A (ja) 2003-10-31 2007-04-19 アルタナ　ファルマ　アクチエンゲゼルシャフト 呼吸器疾患の治療のためのｂｈ４の使用
JP5184783B2 (ja) 2003-11-17 2013-04-17 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリン、及びテトラヒドロビオプテリン類似体の製造方法
EP1687308B1 (en) 2003-11-17 2019-06-12 Merck & Cie Process for preparating (6R)-L-erythrotetrahydrobiopterin hydrochloride crystalline form B from other crystalline forms
KR20070084270A (ko) 2004-11-17 2007-08-24 바이오마린 파머수티컬 인크. 안정한 정제 제형물
JP2008523090A (ja) 2004-12-08 2008-07-03 バイオマリン ファーマシューティカル インコーポレイテッド 新生児肺高血圧症の治療のための方法および組成物
BRPI0609421B1 (pt) 2005-04-28 2021-06-01 Shiratori Pharmaceutical Co., Ltd. Processos para produção de um composto 1,1-bis-alquil sulfonila, para produção de um composto aldeído, e para produção de um derivado de hidrazona
US20080075666A1 (en) 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
EA017064B1 (ru) 2008-03-10 2012-09-28 Такеда Фармасьютикал Компани Лимитед Кристаллическое производное бензимидазола
WO2010017570A2 (de) 2008-08-12 2010-02-18 Orpha Swiss Gmbh Pharmazeutische darreichungsform enthaltend tetrahydrobiopterin
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
CA2771432A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
EP2562176B1 (en) 2010-04-22 2018-08-15 Nihon University Medicinal agent and beverage/food for preventing cerebral dysfunction and improving same
US9884909B2 (en) * 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
CN103458900A (zh) 2011-03-01 2013-12-18 鲁必康研究私人有限公司 四氢生物蝶呤的稳定组合物
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
EP3468534A4 (en) 2016-06-13 2020-02-05 Meharry Medical College MODULATION OF THE NITROGEN OXIDE SYNTHASE SIGNAL PATH FOR ORAL HEALTH
WO2018019931A1 (en) 2016-07-29 2018-02-01 Dipharma S.A. Pharmaceutical composition kit comprising sapropterin dihydrochloride
MA46972A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Forme polymorphe de sépiaptérine
MA46973A (fr) 2016-11-29 2019-10-09 Censa Pharmaceuticals Inc Polymorphes de sépiaptérine et leurs sels
TWI765936B (zh) 2016-11-29 2022-06-01 美商東京威力科創Ｆｓｉ股份有限公司 用以對處理腔室中之微電子基板進行處理的平移與旋轉夾頭
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
JP7811085B2 (ja) 2017-09-01 2026-02-04 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
AU2019277372B2 (en) 2018-05-30 2024-12-19 Ptc Therapeutics Mp, Inc. Pharmaceutically acceptable salts of sepiapterin
EP3801534B1 (en) 2018-05-30 2026-02-18 PTC Therapeutics MP, Inc. Treatment of phenylketonuria with sepiapterin
FI3801536T3 (fi) 2018-05-30 2024-08-29 Ptc Therapeutics Mp Inc Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi
IL290321B1 (en) 2019-08-05 2026-04-01 Ptc Therapeutics Inc Use of spiapterin and its metabolites for radiation exposure treatment
IL291565B1 (en) 2019-09-25 2026-04-01 Ptc Therapeutics Inc Method for treating phenylalanine irregularity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4758571A (en) * 1982-03-03 1988-07-19 Kanegafuchi Chemical Industry Company, Limited Pterin derivatives to treat Parkinson's disease
CN1905863A (zh) * 2003-11-17 2007-01-31 生物马林药物股份有限公司 用于治疗代谢紊乱的方法和组合物
CN101678025A (zh) * 2007-04-11 2010-03-24 生物马林药物股份有限公司 四氢生物蝶呤组合物及其测量方法
CN104736539A (zh) * 2012-05-07 2015-06-24 白鸟制药株式会社 墨蝶呤和四氢乳酰蝶呤的制造法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BERNHARD SCHIRCKS等: "Herstellung von (6R,S)-5,6,7,8-Tetrahydro-L-biopterin, 7,8-Dihydro-L-biopterin, L-Sepiapterin, Deoxysepiapterin, (6R,S)-5,6-Dihydrodeoxysepiapterin und 2"-Deoxybiopterin", 《HELVETICA CHIMICA ACTA》 *
WOLFGANG PFLEIDERER等: "Pteridine, LXVIII. Überführung von Biopterin in Sepiapterin und absolute Konfiguration des Sepiapterins", 《CHEMISCHE BERICHTE》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117117299A (zh) * 2023-08-14 2023-11-24 国联汽车动力电池研究院有限责任公司 一种无机硫化物固体电解质及其制备方法

Also Published As

Publication number Publication date
MX391156B (es) 2025-03-21
WO2018102314A1 (en) 2018-06-07
JP7148532B2 (ja) 2022-10-05
EP3548487A1 (en) 2019-10-09
US12325706B2 (en) 2025-06-10
MX2019006207A (es) 2019-11-18
US11130760B2 (en) 2021-09-28
CA3043499A1 (en) 2018-06-07
US20200010469A1 (en) 2020-01-09
EP3548487A4 (en) 2020-04-29
MA46972A (fr) 2019-10-09
US20220081443A1 (en) 2022-03-17
JP2020500931A (ja) 2020-01-16

Similar Documents

Publication Publication Date Title
CN110312721A (zh) 墨蝶呤的多晶型物
CN110248948B (zh) 墨蝶呤及其盐的多晶型物
CN106255685A (zh) 用于预防或治疗疟疾的三氨基嘧啶化合物
EP3565819B1 (en) Solid forms of [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
US12012421B2 (en) Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
US20220119414A1 (en) Solid forms of [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
CA3048771C (en) Solid forms of [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
NZ794827A (en) Polymorphs of sepiapterin and salts thereof
BR122025000511A2 (pt) Forma cristalina de base livre de sepiapterina, composição farmacêutica que a compreende, uso da mesma e método de preparação de uma formulação líquida
BR122025000503A2 (pt) Forma cristalina de base livre de sepiapterina, composição farmacêutica que a compreende, uso da mesma e método de preparação de uma formulação líquida
BR112019010222B1 (pt) Formas d e f cristalinas de base livre de sepiapterina, suas composições, usos e método de preparação de uma formulação líquida compreendendo as mesmas

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Massachusetts, USA

Applicant after: CENSA PHARMACEUTICALS Inc.

Address before: Washington State

Applicant before: CENSA PHARMACEUTICALS Inc.

CB02 Change of applicant information
CB02 Change of applicant information

Address after: new jersey

Applicant after: PTC THERAPEUTICS, Inc.

Address before: Massachusetts, USA

Applicant before: CENSA PHARMACEUTICALS Inc.

CB02 Change of applicant information
CB02 Change of applicant information

Address after: Massachusetts, USA

Applicant after: PTC medical MP company

Address before: new jersey

Applicant before: PTC THERAPEUTICS, Inc.

CB02 Change of applicant information
CB02 Change of applicant information

Address after: new jersey

Applicant after: PTC medical MP company

Address before: Massachusetts, USA

Applicant before: PTC medical MP company

CB02 Change of applicant information